These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25896426)

  • 1. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.
    Rasmussen HB; Bjerre D; Linnet K; Jürgens G; Dalhoff K; Stefansson H; Hankemeier T; Kaddurah-Daouk R; Taboureau O; Brunak S; Houmann T; Jeppesen P; Pagsberg AK; Plessen K; Dyrborg J; Hansen PR; Hansen PE; Hughes T; Werge T;
    Pharmacogenomics; 2015; 16(6):649-65. PubMed ID: 25896426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.
    Her L; Zhu HJ
    Drug Metab Dispos; 2020 Mar; 48(3):230-244. PubMed ID: 31871135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.
    Thomsen R; Rasmussen HB; Linnet K;
    Drug Metab Dispos; 2014 Jan; 42(1):126-33. PubMed ID: 24141856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of genetic variation in carboxylesterase drug metabolism.
    Chen F; Zhang B; Parker RB; Laizure SC
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):131-142. PubMed ID: 29264996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms.
    Wang X; Rida N; Shi J; Wu AH; Bleske BE; Zhu HJ
    Drug Metab Dispos; 2017 Nov; 45(11):1149-1155. PubMed ID: 28838926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient in vitro refolding and functional characterization of recombinant human liver carboxylesterase (CES1) expressed in E. coli.
    Boonyuen U; Promnares K; Junkree S; Day NP; Imwong M
    Protein Expr Purif; 2015 Mar; 107():68-75. PubMed ID: 25462813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
    Zhu HJ; Wang X; Gawronski BE; Brinda BJ; Angiolillo DJ; Markowitz JS
    J Pharmacol Exp Ther; 2013 Mar; 344(3):665-72. PubMed ID: 23275066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.
    Zhu HJ; Appel DI; Johnson JA; Chavin KD; Markowitz JS
    Biochem Pharmacol; 2009 Apr; 77(7):1266-72. PubMed ID: 19185566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics.
    Di L
    Curr Drug Metab; 2019; 20(2):91-102. PubMed ID: 30129408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel procedure with improved resolution and specificity for amplification and differentiation of variants of the gene encoding carboxylesterase 1.
    Bjerre D; Rasmussen HB;
    Pharmacogenet Genomics; 2017 Apr; 27(4):155-158. PubMed ID: 28146010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin.
    Qian Y; Gilliland TK; Markowitz JS
    Chem Biol Interact; 2020 Jan; 316():108914. PubMed ID: 31837295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
    Zhu HJ; Appel DI; Peterson YK; Wang Z; Markowitz JS
    Toxicology; 2010 Apr; 270(2-3):59-65. PubMed ID: 20097249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus.
    Sanford JC; Wang X; Shi J; Barrie ES; Wang D; Zhu HJ; Sadee W
    Pharmacogenet Genomics; 2016 May; 26(5):197-207. PubMed ID: 26871237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Study of Carboxylesterase 1 Protein Isoforms.
    Wang X; Shi J; Zhu HJ
    Proteomics; 2019 Feb; 19(4):e1800288. PubMed ID: 30520264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.
    Shi J; Wang X; Eyler RF; Liang Y; Liu L; Mueller BA; Zhu HJ
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):555-561. PubMed ID: 27228223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
    Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
    Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1.
    Ferrero-Miliani L; Bjerre D; Stage C; Madsen MB; Jűrgens G; Dalhoff KP; Rasmussen HB
    Pharmacogenomics; 2017 Aug; 18(13):1241-1257. PubMed ID: 28786738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.
    Zhu HJ; Markowitz JS
    Drug Metab Dispos; 2009 Feb; 37(2):264-7. PubMed ID: 19022936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Ensemble Docking and Machine Learning in Identification of Therapeutic Agents with Potential Inhibitory Effect on Human CES1.
    Briand E; Thomsen R; Linnet K; Rasmussen HB; Brunak S; Taboureau O
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31362390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.
    Wang X; Wang G; Shi J; Aa J; Comas R; Liang Y; Zhu HJ
    Pharmacogenomics J; 2016 Jun; 16(3):220-30. PubMed ID: 26076923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.